122 related articles for article (PubMed ID: 23025843)
1. Challenges facing ophthalmic start-up companies in developing new devices or medicines.
Stewart WC; Stewart JA; Kruft B; Nelson LA
Acta Ophthalmol; 2013 Feb; 91(1):e81-3. PubMed ID: 23025843
[No Abstract] [Full Text] [Related]
2. Description of Ophthalmic Pharmaceutical and Device Start-Up Companies.
Sharpe RA; Austin JP; Kruft B; Nelson LA; Stewart JA; Stewart WC
Ophthalmic Res; 2015; 54(1):6-9. PubMed ID: 25999058
[TBL] [Abstract][Full Text] [Related]
3. Combination products regulation at the FDA.
Lauritsen KJ; Nguyen T
Clin Pharmacol Ther; 2009 May; 85(5):468-70. PubMed ID: 19381151
[TBL] [Abstract][Full Text] [Related]
4. TRICARE; off-label uses of devices; partial list of examples of unproven drugs, devices, medical treatments or procedures. Final rule.
Office of the Secretary, Department of Defense (DoD)
Fed Regist; 2012 Jun; 77(124):38177-8. PubMed ID: 22737762
[TBL] [Abstract][Full Text] [Related]
5. Understanding physician responsibilities and limitations for drug and device off-label use.
Sclafani AP
Facial Plast Surg Clin North Am; 2007 May; 15(2):251-4, viii. PubMed ID: 17544942
[TBL] [Abstract][Full Text] [Related]
6. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
Basile EM; Tolomeo D; Gluck E
Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
[TBL] [Abstract][Full Text] [Related]
7. Technology: drug and device export reform.
Betz R
J Healthc Resour Manag; 1995 Oct; 13(10):30, 33. PubMed ID: 10151686
[No Abstract] [Full Text] [Related]
8. The regulation of drugs and biologics: fifty years into the future.
Kuhlik BN
Food Drug Law J; 2000; 55(1):21-5. PubMed ID: 12269358
[No Abstract] [Full Text] [Related]
9. The changing environment for technological innovation in health care.
Goodman CS; Gelijns AC
Baxter Health Policy Rev; 1996; 2():267-315. PubMed ID: 11066263
[TBL] [Abstract][Full Text] [Related]
10. Promoting Therapeutic Innovation: What Do We Do About Drug-Device Combinations?
Wang B; Kesselheim AS
JAMA; 2016 Mar; 315(9):857-8. PubMed ID: 26934246
[No Abstract] [Full Text] [Related]
11. High technology ... struggling to balance the promise of innovation with the reality of affordability.
Van Pelt D
State Health Care Am; 1995; ():47-50. PubMed ID: 10168073
[No Abstract] [Full Text] [Related]
12. The need for federal preemption of state tort claims in the context of "new drugs" and premarket-approved medical devices.
Mottes LM
Seton Hall Law Rev; 2011; 41(2):723-63. PubMed ID: 21739761
[No Abstract] [Full Text] [Related]
13. Regulation of medicines and medical devices: contrasts and similarities.
Parvizi N; Woods K
Clin Med (Lond); 2014 Feb; 14(1):6-12. PubMed ID: 24532735
[TBL] [Abstract][Full Text] [Related]
14. Differences between medical devices and drugs.
Browning P
Br J Nurs; 2014 Jun 26-Jul 9; 23(12):S28-9. PubMed ID: 25075388
[No Abstract] [Full Text] [Related]
15. Medical devices on trial, Part I.
Wright D
Med Device Technol; 2002 Dec; 13(10):35-8. PubMed ID: 12575529
[TBL] [Abstract][Full Text] [Related]
16. [Development and evaluation of new drugs and medical devices in Japan--standpoint of regulatory agency].
Maruyama H; Kondo T
Brain Nerve; 2010 Mar; 62(3):263-8. PubMed ID: 20297731
[TBL] [Abstract][Full Text] [Related]
17. A safe pair of hands.
Dean E
Nurs Stand; 2014 Jun; 28(39):61. PubMed ID: 24866673
[TBL] [Abstract][Full Text] [Related]
18. Walking the drug regulatory tightrope.
Dove A
Nat Biotechnol; 2003 May; 21(5):495-8. PubMed ID: 12721571
[No Abstract] [Full Text] [Related]
19. The Canadian perspective: trends in drug and medical device class actions in Canada.
Vernon W
Food Drug Law J; 2006; 61(3):569-76. PubMed ID: 16989040
[No Abstract] [Full Text] [Related]
20. Missing evidence.
Hayes WS
MLO Med Lab Obs; 2008 Oct; 40(10):68. PubMed ID: 18988559
[No Abstract] [Full Text] [Related]
[Next] [New Search]
